BlackRock, Inc. filed Amendment No. 7 to Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 7,361,888 shares of Harmony Biosciences Holdings, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 7,361,888 shares of Harmony Biosciences Holdings, Inc. common stock.
  • Percent of class: The reported position represents 12.6% of the outstanding common stock of Harmony Biosciences Holdings, Inc.
  • Sole voting power: BlackRock disclosed sole voting power over 7,269,051 shares, with zero shares subject to shared voting power.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 7,361,888 shares, with zero shares subject to shared dispositive power.
  • iShares interest: According to the filing, iShares Core S&P Small-Cap ETF holds an interest of more than five percent of the total outstanding common stock of Harmony Biosciences Holdings, Inc.
  • Event date: The date of the event requiring this filing was stated as September 30, 2026.

BlackRock's Amendment No. 7 Filing on Harmony Biosciences Holdings

BlackRock, Inc., organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, filed Amendment No. 7 to Schedule 13G disclosing its beneficial ownership position in Harmony Biosciences Holdings, Inc. (CUSIP: 413197104), whose principal executive offices are located at 630 W Germantown Pike, Suite 215, Plymouth Meeting, PA 19462. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026.

According to the filing, BlackRock reported aggregate beneficial ownership of 7,361,888 shares of common stock, equating to 12.6% of the class. Of those shares, 7,269,051 are subject to sole voting power, while the remaining shares carry no voting power in this filing. BlackRock reported sole dispositive power over the full 7,361,888 shares, with no shared dispositive power disclosed.

The filing noted that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units." The filing further identified iShares Core S&P Small-Cap ETF as a person whose interest in Harmony Biosciences Holdings, Inc. common stock exceeds five percent of the total outstanding shares. BlackRock certified that the securities were acquired and held in the ordinary course of business and not for the purpose of influencing control of the issuer.

What Was Disclosed

BlackRock, Inc. disclosed via Amendment No. 7 to Schedule 13G that, as of September 30, 2026, it beneficially owned 7,361,888 shares, or 12.6%, of Harmony Biosciences Holdings, Inc. common stock, with sole voting power over 7,269,051 of those shares.